000017360 001__ 17360
000017360 005__ 20190625111329.0
000017360 0247_ $$2pmid$$apmid:21791550
000017360 0247_ $$2pmc$$apmc:PMC3298077
000017360 0247_ $$2DOI$$a10.1093/hmg/ddr325
000017360 0247_ $$2WOS$$aWOS:000295171200017
000017360 0247_ $$2altmetric$$aaltmetric:200331
000017360 037__ $$aPreJuSER-17360
000017360 041__ $$aeng
000017360 082__ $$a570
000017360 084__ $$2WoS$$aBiochemistry & Molecular Biology
000017360 084__ $$2WoS$$aGenetics & Heredity
000017360 1001_ $$0P:(DE-HGF)0$$aSteinberg, S.$$b0
000017360 245__ $$aCommon variants at VRK2 and TCF4 conferring risk of schizophrenia
000017360 260__ $$aOxford$$bOxford Univ. Press$$c2011
000017360 300__ $$a4076 - 4081
000017360 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000017360 3367_ $$2DataCite$$aOutput Types/Journal article
000017360 3367_ $$00$$2EndNote$$aJournal Article
000017360 3367_ $$2BibTeX$$aARTICLE
000017360 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000017360 3367_ $$2DRIVER$$aarticle
000017360 440_0 $$09913$$aHuman Molecular Genetics$$v20$$x0964-6906$$y20
000017360 500__ $$3POF3_Assignment on 2016-02-29
000017360 500__ $$aThis work was supported by the European Union [grant numbers LSHM-CT-2006-037761 (Project SGENE), PIAP-GA-2008-218251 (Project PsychGene), HEALTH-F2-2009-223423 (Project PsychCNVs)]; the National Genome Research Network of the German Federal Ministry of Education and Research (BMBF) [grant numbers 01GS08144 (MooDS-Net), 01GS08147 (NGFNplus)]; the National Institute of Mental Health [R01 MH078075, and N01 MH900001, MH074027 to the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project]; the Centre of Excellence for Complex Disease Genetics of the Academy of Finland (grant numbers 213506, 129680); the Biocentrum Helsinki Foundation and Research Program for Molecular Medicine, Faculty of Medicine, University of Helsinki; the Stanley Medical Research Institute; the Danish Council for Strategic Research (grant number 2101-07-0059); H. Lundbeck A/S; the Research Council of Norway (grant number 163070/V50); the South-East Norway Health Authority (grant number 2004-123); the Medical Research Council; Ministerio de Sanidad y Consumo, Spain (grant number PI081522 to J.C.); Xunta de Galicia (grant number 08CSA005208PR to A.C.); the Swedish Research Council; the Wellcome Trust (grant number 083948/Z/07/Z as part of the Wellcome Trust Case Control Consortium 2); the Max Planck Society and Eli Lilly and Company (genotyping for CATIE and part of the TOP sample).
000017360 520__ $$aCommon sequence variants have recently joined rare structural polymorphisms as genetic factors with strong evidence for association with schizophrenia. Here we extend our previous genome-wide association study and meta-analysis (totalling 7 946 cases and 19 036 controls) by examining an expanded set of variants using an enlarged follow-up sample (up to 10 260 cases and 23 500 controls). In addition to previously reported alleles in the major histocompatibility complex region, near neurogranin (NRGN) and in an intron of transcription factor 4 (TCF4), we find two novel variants showing genome-wide significant association: rs2312147[C], upstream of vaccinia-related kinase 2 (VRK2) [odds ratio (OR) = 1.09, P = 1.9 × 10(-9)] and rs4309482[A], between coiled-coiled domain containing 68 (CCDC68) and TCF4, about 400 kb from the previously described risk allele, but not accounted for by its association (OR = 1.09, P = 7.8 × 10(-9)).
000017360 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000017360 536__ $$0G:(EU-Grant)218251$$aPSYCHGENE - Copy Number Variation and Endophenotypes in Psychiatric Disorders (218251)$$c218251$$fFP7-PEOPLE-2007-3-1-IAPP$$x1
000017360 536__ $$0G:(EU-Grant)223423$$aPSYCHCNVS - Copy number variations conferring risk of psychiatric disorders in children (223423)$$c223423$$fFP7-HEALTH-2007-B$$x2
000017360 588__ $$aDataset connected to Web of Science, Pubmed
000017360 650_2 $$2MeSH$$aAlleles
000017360 650_2 $$2MeSH$$aBasic Helix-Loop-Helix Leucine Zipper Transcription Factors: genetics
000017360 650_2 $$2MeSH$$aGenetic Predisposition to Disease
000017360 650_2 $$2MeSH$$aGenome-Wide Association Study
000017360 650_2 $$2MeSH$$aGenotype
000017360 650_2 $$2MeSH$$aHumans
000017360 650_2 $$2MeSH$$aPolymorphism, Single Nucleotide
000017360 650_2 $$2MeSH$$aProtein-Serine-Threonine Kinases: genetics
000017360 650_2 $$2MeSH$$aRisk
000017360 650_2 $$2MeSH$$aSchizophrenia: genetics
000017360 650_2 $$2MeSH$$aTranscription Factors: genetics
000017360 650_7 $$00$$2NLM Chemicals$$aBasic Helix-Loop-Helix Leucine Zipper Transcription Factors
000017360 650_7 $$00$$2NLM Chemicals$$aTCF4 protein, human
000017360 650_7 $$00$$2NLM Chemicals$$aTranscription Factors
000017360 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aProtein-Serine-Threonine Kinases
000017360 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aVRK2 protein, human
000017360 650_7 $$2WoSType$$aJ
000017360 7001_ $$0P:(DE-Juel1)VDB90383$$aet, al.$$b1$$uFZJ
000017360 773__ $$0PERI:(DE-600)1474816-2$$a10.1093/hmg/ddr325$$gVol. 20, p. 4076 - 4081$$p4076 - 4081$$q20<4076 - 4081$$tHuman molecular genetics$$v20$$x0964-6906$$y2011
000017360 8567_ $$2Pubmed Central$$uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298077
000017360 909CO $$ooai:juser.fz-juelich.de:17360$$pec_fundedresources$$pVDB$$popenaire
000017360 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000017360 9141_ $$y2011
000017360 9131_ $$0G:(DE-Juel1)FUEK409$$aDE-HGF$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000017360 9132_ $$0G:(DE-HGF)POF3-579H$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vAddenda$$x0
000017360 9201_ $$0I:(DE-Juel1)INM-1-20090406$$gINM$$kINM-1$$lStrukturelle und funktionelle Organisation des Gehirns$$x0
000017360 970__ $$aVDB:(DE-Juel1)131816
000017360 980__ $$aVDB
000017360 980__ $$aConvertedRecord
000017360 980__ $$ajournal
000017360 980__ $$aI:(DE-Juel1)INM-1-20090406
000017360 980__ $$aUNRESTRICTED